In fact, overexpression of FAM150B in the Th-Mycn neuroblastoma mouse model (which has no ALK-activating mutations) induced tumours that are sensitive to tyrosine kinase inhibitor (TKI) treatment, while ALK mutations confer resistance [102]. This evidence concerns the gene ALK and neuroblastoma.